Why the feds are justified in taking a harder line against longer pharma patents
Right-wing ideologues and corporate sycophants are attacking plans by the White House to shorten the patent exclusivity of biological drugs from twelve years to seven. But the pharmaceutical industry has only its own conduct over the past decade to blame.